A new clinical trial in Houston is offering hope to men struggling with pattern hair loss (PHA), also known as androgenetic alopecia (AGA), the most common form of hair loss affecting millions worldwide. This trial is testing an investigational, non-hormonal oral tablet called VDPHL01, which could potentially address the treatment gap for men with PHA.
Currently, there are no FDA-approved treatments like this available, and existing options often come with frustrating side effects such as sexual dysfunction and heart-related issues. For many, these limitations have led to a search for better alternatives. Dr. Megan Couvillion, Principal Investigator and Dermatologist at SBA Dermatology, emphasized the importance of this trial, highlighting that many patients are seeking new treatments that don’t come with serious side effects.
The clinical trial, which is now enrolling participants, aims to provide a solution for men who have struggled to find effective treatments for hair loss. The study will last 13 months, during which participants will receive either the study drug or a placebo. At the six-month mark, all participants will be given the study medication for the remainder of the trial. Participants must be male, aged 18-65, in good general health, and willing to follow specific hair care guidelines throughout the study.
Participants will receive compensation for their time and the study medication at no cost. This trial represents a significant step forward in the search for effective, non-hormonal hair loss treatments.
Related topics:
- Burgundy: The Most Fashionable Hair Color of 2025
- Hairstylists Exposed to Harmful Chemicals in the Workplace
- Giovanni Eco Chic Beauty Co-Presents 2025 MUAHS Awards with L’Oréal
